Julian S. Gangolli - Oct 1, 2025 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Director
Signature
/s/Lawrence A. Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Oct 1, 2025
Transactions value $
$0
Form type
4
Date filed
10/3/2025, 07:45 PM
Previous filing
Jun 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gangolli Julian S Director C/O OUTLOOK THERAPEUTICS, INC., 111 S. WOOD AVE, UNIT #100, ISELIN /s/Lawrence A. Kenyon, Attorney-in-Fact 2025-10-03 0001532023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +287K $0.00 287K Oct 1, 2025 Common Stock 287K $1.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.